Abstract Sporadic Alzheimer's disease (sAD) is the most common form of dementia. Rats injected intracerebroventricularly with streptozotocin (STZ-icv) develop insulin-resistant brain state and represent a non-transgenic sAD model with a number of AD-like cognitive and neurochemical features. We explored cognitive, structural and ultrastructural changes in the brain of the STZ-icv rat model over a course of 9 months. Cognitive functions were measured in the STZ-icv-(0.3, 1 and 3 mg/kg) and age-matched control rats by passive avoidance test. Structural changes were assessed by Nissl and Bielschowsky silver staining. Immunohistochemistry and electron microscopy analysis were used to detect amyloid b-(Ab 1-42 ) and hyperphosphorylated tau (AT8) accumulation and ultrastructural changes in the brain. Memory decline was time-(B3 months/acute, C3 months/progressive) and STZ-icv dose-dependent. Morphological changes were manifested as thinning of parietal cortex (C1 month) and corpus callosum (9 months), and were more pronounced in the 3 mg/kg STZ group. Early neurofibrillary changes (AT8) were detected from 1 month onward in the neocortex, and progressed after 3 months to the hippocampus. Intracellular Ab 1-42 accumulation was found in the neocortex at 3 months following STZ-icv treatment, while diffuse Ab 1-42 -positive plaque-like formations were found after 6 months in the neocortex and hippocampus. Ultrastructural changes revealed enlargement of Golgi apparatus, pyknotic nuclei, and time-dependent increase in lysosome size, number, and density. Our data provide a staging of cognitive, structural/ultrastructural, and neuropathological markers in the STZ-icv rat model that in many aspects seems to be generally comparable to stages seen in human sAD.
Introduction
Alzheimer's disease (AD) is the most common form of dementia, clinically characterized by a progressive memory loss. The major neuropathological hallmarks of AD are senile (amyloid) plaques and neurofibrillary tangles (NFTs) that demonstrate regionally specific distribution in cerebral cortex and in certain subcortical nuclei Braak 1991, 1995; Selkoe 2001; Thal et al. 2002b ). Amyloid b 1-42 (Ab ) is the main component of senile plaques, which may occur as diffuse plaques, intermingled amongst neuronal processes that appear to remain unaffected by this process, and compact or cored plaques that damage brain tissue. The latter induce microglia and astrocyte activation, and are typically surrounded by dystrophic, tau-containing neurites. Hyperphosporylated tau protein is the main component of NFTs, which are located in the cytoplasm of neuronal cell bodies and neuritic processes (Buee et al. 2000; Hinrichs et al. 2012; Simic et al. 1998) .
Contrary to the rare and inherited early-onset form of AD, the cause of the prevailing, sporadic late-onset AD form (sAD) is unknown. In addition to the various mechanisms of neural degeneration, like mitochondrial dysfunction (Diana et al. 2008 ) and oxidative stress (Leuner et al. 2012; Simic et al. 2009 ; Thome et al. 1997; Völkel et al. 2006) , or environmental factors (Shaw and Höglinger 2008) suggested to play a role in the etiopathogenesis of sAD, evidence supports the concept of brain insulin resistance and metabolic dysfunction being important mediators of pathophysiological changes in sAD (Correia et al. 2011; De Felice et al. 2014; de la Monte and Tong 2014; Hoyer 2004; Salkovic-Petrisic et al. 2009 ). Modeling of brain insulin resistance is therefore relevant in this respect but has not been sufficiently studied. The identification of diseasecausing mutations in proteins such as Ab precursor protein (APP) and presenillins 1 and 2 (PS1, PS2) as well as pathogenic mutations in tau protein, resulted in the development of many transgenic mice AD models (Lithner et al. 2011) . However, such models are representative for rare familial AD forms and their reliability as models for sAD has been recently questioned as well as their actual use in AD drug discovery (Bales 2012; Zahs and Ashe 2010) . Amyloid-related gene manipulation in transgenic mice AD models is inevitable starting point as antecedent to Ab pathology as well as to brain insulin dysfunction whose development differs between the transgenic mice AD models (Chen et al. 2013; Niwa et al. 2002; Pedersen et al. 2006; Pedrós et al. 2014) . For this reason, transgenic mice AD models are inappropriate for exploring the cause, onset and development of the pathological Ab deposition in the brain in a condition that is not associated with mutations of the APP/PS1 genes and in which brain insulin dysfunction might precede Ab pathology (like in sAD).
A different approach that does not involve genetic engineering has been used to generate a non-transgenic rat model of insulin resistance in the brain by intracerebroventricular (icv) injection of streptozotocin (STZ-icv model) (Lannert and Hoyer 1998) . STZ (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose)) is a cytotoxic compound that acts selectively on insulin-producing/secreting cells and causes type 1 diabetes mellitus in adult rats following parenteral administration at high doses (Szkudelski 2001) . Multiple parenteral treatments with low-to-moderate STZ doses cause insulin resistance and type 2 diabetes mellitus by affecting insulin receptor (IR) signaling (Blondel and Portha 1989; Giorgino et al. 1992; Kadowaki et al. 1984) . Icv administration of low STZ doses does not induce a systemic diabetic condition in rats, but has been convincingly shown to induce insulin-resistant brain state characterized by altered tyrosine kinase activity of IR and dysfunctional signaling downstream the IR signaling pathways (Agrawal et al. 2010 (Agrawal et al. , 2011 Grünblatt et al. 2007; Lester-Coll et al. 2006; Osmanovic-Barilar et al. 2014; Salkovic-Petrisic et al. 2006; Steen et al. 2005) , accompanied by a decrease in brain glucose and energy metabolism (Hoyer and Lannert 2007; Lannert and Hoyer 1998; Nitsch and Hoyer 1991; Plaschke and Hoyer 1993) . Additionally, the STZ-icv rat model has been demonstrated to develop remarkable behavioral and neuropathological AD-like features, in particular cognitive (Mayer et al. 1990 ) and brain cholinergic deficits (Hellweg et al. 1992) , as well as oxidative stress (Correia et al. 2013; Sharma and Gupta 2001) , neuroinflammation, and astrogliosis (Chen et al. 2013; Javed et al. 2011; Kraska et al. 2012; Prickaerts et al. 1999 Prickaerts et al. , 2000 Rodrigues et al. 2010; Shoham et al. 2003 Shoham et al. , 2007 . Severely affected STZ-icv rats also demonstrate extensive cell loss, inferred from increase in the volume of the ventricular system (Kraska et al. 2012; Prickaerts et al. 2000; Shoham et al. 2003) , and a significant enlargement of the trans-Golgi compartment in cortical neurons at the ultrastructural level (Grieb et al. 2004 ). In addition, increased Ab 1-42 and hyperphosphorylated tau immunoreactivity have been detected in the hippocampus of STZ-icv rats and mice (Chen et al. 2013; Correia et al. 2013; Deng et al. 2009; Kosaraju et al. 2013; Shingo et al. 2012 ). Accumulation of Ab in the cerebral microvasculature (cerebral amyloid angiopathy, CAA) has been observed first in the meningeal capillaries (Salkovic-Petrisic et al. 2006) , progressing subsequently to the intracortical blood vessels of STZ-icv rats (Salkovic-Petrisic et al. 2011) .
With the exception of a long-term follow-up of CAA development (Salkovic-Petrisic et al. 2013 ) and dysfunction in IR signaling cascade (Osmanovic-Barilar et al. 2014) , there have been no reports on neurochemical or neuropathological changes in the brain or of cognitive deficits in STZ-icv models investigated in periods of more than 6 months after STZ injection. To characterize and validate the model better, in this 9-month follow-up study, we have assessed the onset, development, and progression of Ab 1-42 and hyperphosphorylated tau immunopositive lesions, ultrastructural changes in the brain, as well as cognitive deficits in the STZ-icv rats as a function of STZ dose and post-treatment time.
Materials and methods

Chemicals
Streptozotocin was purchased from Sigma-Aldrich Chemie (Munich, Germany). Phospho-PHF-tau pSer202/Thr205 monoclonal antibody (AT8, cat. no. MN1020) was purchased from Thermo Scientific (Waltham, MA, USA). Monoclonal antibodies against amyloid b 1-42 were purchased from Signet, (Signet Laboratories, Inc., Dedham, MA, USA, 2006, cat. No. 39142) and from Covance (Princeton, NJ, USA; clone 12F4, cat. No. 39142 and cat. No. 39136) . Vectastain Elite ABC Kit (Cat. No. PK-6200) while normal goat serum (S-1000), biotinylated goat antimouse IgG antibody (cat. no. BA-9200) and ImmPACT AEC peroxidase substrate (cat. no. SK-4205) were purchased from Vector Laboratories (Burlingame, CA, USA). Paraformaldehyde was purchased from Sigma-Aldrich (cat. no. 16005, St. Louis, MO, USA). MultiLink-HRP kit was purchased from Biogenex (cat. no. LP000-UL, San Ramon, CA, USA) and Romulin AEC chromogen was purchased from Biocarta (cat. no. RAEC810L, San Diego, CA, USA).
Animals
Three-month-old male Wistar rats weighing 280-350 g (Department of Pharmacology, University of Zagreb School of Medicine) were used in all experiments. The rats were kept 2-3 per cage in a room with a 12 h light/12 h dark cycle (lights on 07:00-19:00 h), and the room temperature and humidity set in the range of 21-25°C and 40-70 %, respectively. All animals were kept on standardized food pellets and water ad libitum.
Surgery
Rats were subjected to deep general anesthesia (chloral hydrate 300 mg/kg, ip, Merck, Darmstadt, Germany), followed by icv injection of STZ (0.3, 1 or 3 mg/kg, dissolved in 0.05 M citrate buffer, pH 4.5, bilaterally 2 ll/ventricle split in two doses given on days 1 and 3), according to the procedure first described by Noble et al. (1967) and used elsewhere (Grünblatt et al. 2007; Lackovic and Salkovic 1990; Osmanovic-Barilar et al. 2014; Salkovic-Petrisic et al. 2011; Salkovic et al. 1995) . Control animals were given an equal volume of vehicle icv by the same procedure on days 1 and 3.
Experimental design
STZ-icv (0.3, 1, or 3 mg/kg) and respective age-matched control (treated icv with 0.05 M citrate buffer, pH 4.5) animals were killled after 1 week, and 1, 3, 6, or 9 months following the treatment, respectively. Cognitive testing was performed immediately before killing at each time point (N = 8-10 per group, four groups per experiment: control, STZ 0.3 mg/kg, STZ 1 mg/kg, STZ 3 mg/kg). In additional set of experiments, rats treated with high (3 mg/ kg) STZ-icv dose and age-matched controls were killed 2 weeks, and 1, 3, 6 and 9 months after the treatment (two groups per experiment: control, STZ 3 mg/kg). Animals were euthanized in deep anesthesia (thiopental:diazepam 50:6 mg/kg intraperitoneally) followed by decapitation in all experiments.
Cognitive testing
Memory functions were tested by passive avoidance test with a step-through type passive avoidance task (Ugo Basile, Comerio, Italy) utilizing the natural preference of rats for dark environments. It is a fear-motivated avoidance task in which rats learn to refrain from stepping through a door to an apparently safer but previously punishment-related dark compartment. The latency to refrain from crossing into the punishing compartment serves as an index of the ability to avoid, and allows memory assessment. Those rats that had no alterations in memory functions (vehicle-treated controls) had to remember that a foot shock would follow entering the dark compartment (therefore, had to stay longer in the lit compartment on the test day). In case of impaired memory functions, rats would not associate the foot shock with the dark environment and spend less time in the lit compartment. Passive avoidance test performance lasts for 3 days starting with a habituation day to make the rat familiar with the environment (without foot shock, or pre-shock latency), followed by a training day in which foot shock (0.3-0.5 mA, depending on the rat weight, duration 2 s) is delivered; and finally a testing day (without foot shock). Time required for entrance of a rat into the dark compartment was measured with a cut-off time of 5 min. In all of the experiments, passive avoidance test was performed only once per group/experiment.
Tissue preparation
Animals were deeply anesthetized with chloral hydrate (300 mg/kg ip) or thiopental:diazepam (50:6 mg/kg ip) and perfused with saline followed by 4 % paraformaldehyde, pH 7.4 in a standard procedure. Brains were quickly removed and embedded in paraffin, then cut on a sliding microtome into 8-lm-thick sections. Tissue sections were mounted on slides and dried by leaving the slide at room temperature overnight. Tissue sections for Ab immunohistochemistry were obtained from animals in experiments (3 mg STZ-icv only) different from those used for cognitive testing and structural tau protein and electron microscopy analysis.
Immunohistochemistry
The slides were first deparaffinized and rehydrated. Before immunohistochemical staining with AT8 and monoclonal Staging of cognitive deficits 579
antibodies against Ab 1-42 , slides were subjected to antigen retrieval step (1 h in 80 % formic acid for Ab 1-42 immunostaining, and 30 min on 95°C in sodium citrate buffer, pH 6.0) and then washed and incubated in 0.7 % H 2 O 2 for 15 min. Slides were then washed in TBS (pH 7.6) and blocked with 10 % normal goat serum for 1 h and incubated with primary antibodies AT8 (1:100) and Ab (1:2000) diluted in TBS with 1 % BSA overnight at 4°C. Next day, slides (incubated with AT8) were washed and incubated with biotinylated secondary goat anti-mouse antibody for 1 h, followed by incubation with Vectastain ABC kit for 30 min. Immunoreaction was developed by incubation with ABC peroxidase substrate kit for 4 min. Slides were counterstained with haematoxylin for 1 min, washed with H 2 O and mounted. Slides incubated with Ab 1-42 were incubated with MultiLink kit following the manufacturer's protocol. The reaction was developed by incubation with Romulin AEC chromogen for 4 min. Slides were then counterstained with haematoxylin, washed, dehydrated, and mounted. Specific positive Ab 1-42 signal in the rat brain was obtained by antibody purchased from Signet (Dedham, MA, USA).
Immunohistochemistry was performed on four sections per brain (number of animals per group: 1-2 for Ab 1-42 and 3-4 for AT8). Human AD brain tissue samples were used as a positive control in both AT8 and Ab 1-42 immunohistochemistry.
Bielschowsky silver staining
Slides were deparaffinized and rehydrated, and then incubated for 20 min in the dark with a 20 % AgNO 3 solution. Slides were then washed with dH 2 O and incubated for another 15 min with the same solution but with added ammonium, and washed in dH 2 O with ammonium. Then slides were incubated for 3-5 min or until they darken in the AgNO 3 /ammonium solution with developer (20 ml of formalin, a drop of concentrated HNO 3 , 0.5 g of citric acid, and 100 ml of dH 2 O) and then washed and fixated in 5 % sodium thiosulfate for 5 min (Uchihara 2007) . Slides were then washed, dehydrated, and mounted.
Nissl staining
Slides were deparaffinized and rehydrated and after that the slides were stained in 0.5 % cresyl violet solution diluted with dH 2 O (ratio 1:4) until it darkens. Slides were then washed with dH 2 O and differentiated in 70 % ethyl alcohol with 2-3 drops of 10 % acetic acid. After differentiation slides were dehydrated in 70 % ethyl alcohol, followed by 96 and 100 % ethyl alcohol and cleared in xylene and mounted with permanent mounting medium.
Electron microscopy
The animals were anesthetized and transcardially perfused using 6 % glutaraldehyde in 0. 
Statistics
The significance of between-group differences in the passive avoidance test (mean ± SD) was tested by KruskalWallis one-way analysis of variance (ANOVA) followed by Mann-Whitney U test, with significance set at a = 0.05. Quantitative analysis of the signal captured by Bielschowsky silver and Nissl staining (N = 4 per group, two sections per brain) was done by cellSense Dimension software and further statistical analysis (mean ± SD) was done by Kruskal-Wallis and Mann-Whitney U test (p \ 0.05).
Results
Cognitive deficits
Compared to the age-matched controls, STZ-icv rats demonstrated severe cognitive deficits manifested as lower post-shock latency time in the passive avoidance test observed from 1 to 9 months (Fig. 1) . Lower latency time in STZ-icv rats indicated diminished capacity to remember that entering into the dark compartment would result in being subjected to an electric shock. Memory impairment in STZ-icv rats was clearly dose-dependent and most pronounced with the highest STZ-icv dose used (up to -95 % compared to controls, p \ 0.05; Fig. 1 ). Additionally, cognitive deficits were time-dependent, showing a specific time pattern of changes with all three doses; pronounced acute cognitive decline 1 month after STZ treatment (phase I), partial or complete improvement of memory impairment at month 3 (phase II), followed by a slow chronic cognitive decline persisting up to 9 months after the STZ-icv treatment (phase III), which was sustained and progressive at medium and high STZ doses (p \ 0.05; Fig. 1 ). Although such a time-pattern of cognitive deficits was evident with all three doses, only the lowest (0.03 mg/kg) STZ dose regime was associated with full reversibility of acute cognitive decline (latency time not different from the control group after 3 months), and partial reversibility of chronic cognitive decline (cognitive deficit persisted but was much lower in comparison to medium-and high-dose regimes, p \ 0.05) at month 9 ( Fig. 1) . Analysis of individual latency time (data not shown) revealed subgroups within each STZ-icv group: subgroup 1 with latency time close to controls (298 s) and subgroup 2 with values substantially lower than controls (40-50 s). While the ratio of animals between subgroups 1 and 2 was B2 vs C9 in each STZ-icv treated-group at month 1, indicating a severe acute response regardless of the dose, dose-dependent reduction in subgroup 1, and increment in subgroup 2 at month 3 (7 vs 3, 5 vs 5 and 2 vs 8 in 0.3, 1, and 3 mg/kg group, respectively) indicated that early pathology is fully compensated in some animals but not in others of the same dose group.
Morphological changes
Nissl and Bielschowsky silver staining showed that morphologic changes after STZ-icv treatment are dose-dependent (more pronounced with a high dose) and that the cerebral cortex is affected earlier than the corpus callosum (Figs. 2, 3) . Bielschowsky silver staining demonstrated fiber loss in corpus callosum with high (-31 %, p \ 0.05) and medium (-10 %, p \ 0.05) STZ-icv dose 9 months after the treatment but did not reveal any silver-stained plaques or NFTs at any of the time points regardless of the dose (Fig. 2) . Nissl staining also showed dose-dependent pathological changes in the brain of STZ-icv-treated rats particularly as a reduction of cortical thickness (Fig. 3) . The thickness of the parietal cortex dropped in STZ-icv treated rats 1 month after treatment with medium (-5 %, p \ 0.05) and high (-11 %, p \ 0.05) doses compared to age-matched controls, and in high-dose compared to lowdose STZ-icv rats (-11 %, p \ 0.05; Fig. 3 ). Although mild, the effect was stable thereafter and present in medium-and high-dose compared to low-dose STZ-icv-treated rats (-7 % both doses, p \ 0.05) after 6 months and in high-dose STZ-icv-treated rat compared to all other groups (-11 %, p \ 0.05) after 9 months (Fig. 3) .
Amyloid pathology
Staging of amyloid pathology development in the rat brain was assessed following the treatment with high STZ-icv dose (3 mg/kg) in comparison to age-matched controls. Ab 1-42 immunoreactivity was first seen 3 months following the STZ-icv treatment in the form of intraneuronal Ab 1-42 accumulation in the parietal cortex (Fig. 4b, c) . Extracellular Ab 1-42 immunoreactivity in the form of aggregates that resembled human primitive plaques was found in places in the neocortex and hippocampus 6 months following the STZ-icv treatment (Fig. 4e, f) . These Ab 1-42 -positive plaque-like formations were found in higher number and concentrated in the external capsule 9 months following STZ-icv treatment (Fig. 4h, i) . No plaque-like Ab 1-42 immunoreactivity has been found in the control animals at any of the time points, while intraneuronal Ab 1-42 immunoreactivity of low intensity was seen in only few cortical neurons of control rats only 9 months after icv 
AT8 immunohistochemistry
Staging of tau protein pathology development in the rat brain was explored following the treatment with high STZicv dose (3 mg/kg) in comparison to the age-matched controls. Immunocytochemistry revealed positive AT8 signal in STZ-icv-treated rats which indicated numerous early neurofibrillary changes (Fig. 5) . Intracellular AT8 immunoreactivity was detected starting from 1 month after STZ-icv injection in the dispersed area of temporal cortex ( Fig. 5b, c ; Table 1 ). Interestingly, at the same time point and at the same cortical location, much less intensive and more focused positive AT8 signal was also observed in the control animals ( Fig. 5a ; Table 1 ), Positive AT8 signal of same intensity and only at this location has been observed also in the controls at 3-and 6-month time points and has vanished at 9-month time point Table 1 ), suggesting that it might be a non-specific response to icv injection. In contrast to the controls, the intensity of AT8 immunoreactivity in the temporal cortex of STZ-icv treated animals progressed with duration of the post-treatment time, and eventually started to appear additionally in the parietal cortex (Fig. 5e , f) and hippocampal areas CA1 and CA3 and dentate gyrus (granullar cells) where it was detected from 3 months after the STZ-icv treatment onward (Table 1 ). The signal was particularly intensive at 6-and 9-month time points post STZ-icv treatment (3 mg/kg) ( Fig. 5h -j, l-n). Human AD brain tissue samples were used as a positive control (data not shown). Fig. 2 Staging of fiber loss in the rat corpus callosum following streptozotocin treatment (Bielschowsky silver staining). Quantitative analysis of thickness of the corpus callosum from the streptozotocin (STZ)-treated (0.3, 1, and 3 mg/kg) and age-matched control (CTRL) rats collected 1 week, and 1, 3, 6, and 9 months following the icv treatment is presented as a time curve with statistically significant changes presented additionally as bars (mean ± SD). Since the significant difference between the groups by Kruskal-Wallis test was detected only at 9-month time point only, respective (representative) microphotographs of the brain from the STZ (0.3, 1, and 3 mg/kg) and age-matched CTRL rats collected 9 months following the icv treatment are presented only. White arrows on microphotographs point to the corpus callosum. Images were taken at matching coronal level. 
Electron microscopy
The granule cell layer of the dentate gyrus and the external granular and pyramidal neocortical layers were assessed for ultrastructural changes by electron microscopy. The ultrastructural analysis of the selected areas showed timedependent increase in number, size, and electron density of lysosomes in the cytoplasm of neurons from the STZ-icv (3 mg/kg) treated rat brains (Table 1 ), while very rare lysosomes of constant size and density were found in agematched control animals ( Fig. 6i ; Table 1 ). In the STZ-icvtreated animals, the most abundant and largest lysosomes with compact dark granular content were found in the granule cell layer of the dentate gyrus 6 and 9 months after the STZ-icv treatment ( Fig. 6b-d ; Table 1 ). Unlike the cognitive and structural changes mentioned above, some ultrastructural changes were seen as early as 1 week after STZ-icv treatment (Table 1) . Irregular shape of neuronal nuclei with nuclear envelope invagination as well as the presence of concentrated nucleus and nucleolus with higher electron density (pyknotic nuclei) was found starting already from 1 week after the STZ-icv treatment (Table 1) . The changes progressed and were pronounced 6 and 9 months following the STZ-icv treatment (3 mg/kg) ( Fig. 6f-h ; Table 1 ). Finally, enlargement of the Golgi apparatus was observed and pronounced particularly 6 and 9 months after the STZ-icv treatment (3 mg/kg) ( Fig. 6g ; Table 1 ). Fig. 3 Staging of the cortical loss following streptozotocin treatment in rats (Nissl staining). Quantitative analysis of thickness of the parietal cortex from the streptozotocin (STZ)-treated (0.3, 1, and 3 mg/kg) and age-matched control (CTRL) rats collected 1 week, 1 month, 3, 6 and 9 months following the icv treatment is presented as a time curve with statistically significant changes presented additionally as bars (mean ± SD). The significant difference between the groups by Kruskal-Wallis test was detected at 1-, 3-and 9-month time points and respective (representative) microphotographs of the brain from the STZ-icv treated (0.3, 1, and 3 mg/kg) and age-matched control rats are presented as well. White arrows on microphotographs point to the parietal cortex. Images were taken at matching coronal level. 
Discussion
The STZ-icv rat model recapitulates most of the sAD pathological features. Central administration of low STZ doses causes an insulin-resistant brain state (Agrawal et al. 2010 (Agrawal et al. , 2011 Chen et al. 2013; Grünblatt et al. 2007; LesterColl et al. 2006; Salkovic-Petrisic et al. 2006; Steen et al. 2005 ) which has been found also post-mortem in the brain of patients with sAD (de la Frö-lich et al. 1999; Steen et al. 2005) . Additionally, STZ-icv treated rats demonstrate cognitive deficits, glucose hypometabolism and cholinergic deficit as well as oxidative stress and astrogliosis in the brain, respectively (as reviewed elsewhere, Salkovic-Petrisic and Hoyer 2007) .
Beside rats, mice (Pinton et al. 2011; Plaschke et al. 2010) and monkeys (Heo et al. 2011; Park et al. 2013 ) also generate reproducibly these AD-like features following the STZ-icv treatment. The STZ-icv treated rat represents an inducible model that circumvents generating genetically modified animals. The follow-up of AD-like pathology onset, development, and progression in this model could contribute to elucidation of sAD etiopathogenesis as its earliest stages remain unknown in human. So far, the STZicv model had been characterized up to 3 months after STZ-icv administration, which is insufficient to reproduce the human disease process that takes several decades to develop. Here, we present evidence of diffuse Ab 1-42 plaque-like formations, accumulation of c) while starting from the 6-month time point (e, f) up to 9 months (h, i), positive signals of both intra-and extracellular primitive plaquelike Ab 1-42 accumulation were found predominantly in the parietal cortex (f small insert) and subhippocampal thalamic region and to a lesser extent in the hippocampus. Scale bar 100 lm, except for i and a small insert at f: scale bar 10 lm hyperphosphorylated AT8 tau protein and ultrastructural changes, as well as cognitive deficits, which all develop in a time-and STZ-icv dose-dependent manner during a course of 9 months. Cognitive deficits have demonstrated a clear time pattern with acute decline observed after 1 month and a slow but progressive chronic decline seen from 3 months after STZ-icv treatment. It can be speculated that the intensive acute response seen after 1 month may reflect toxic effects of STZ (a cytotoxic compound known to induce nitrosative stress within the cell; Szkudelski 2001), which can be partly compensated until 3 months after the STZ-icv treatment (Figs. 1, 7) . This tendency for compensation of acute memory impairment at 3 months demonstrated a clear dose-dependent effect. Our results indicate that a time of 3 months after the STZ-icv treatment seems to be a critical point at which the pathological processes initiated by icv injection of moderate to high STZ doses could not be compensated any longer, resulting in a slow and progressive memory decline. Additionally, measurement of cognitive deficit at 1-and 3-months demonstrated subgrouping within each STZ-icv group clearly indicating that cognitive pathology is completely compensated in a dosedependent manner in some animals, which allows for a comparison of these early stages in STZ-icv model to mild cognitive impairment (MCI) in humans in which roughly 35 % of affected patients progress to AD (Mitchell 2009 ). Our results are in line with the previous findings showing Fig. 5 Immunoreactivity of hyperphosphorylated tau protein in the brain of STZ-icv-treated rats, visualized by AT8 immunohistochemistry. The figure shows representative microphotographs of the brain from the streptozotocin (STZ, 3 mg/kg)-treated rats (b, c, e, f, h-j, ln) and age-matched controls (CTRL) (a, d, g, k) obtained 1 month, 3, 6 and 9 months following the treatment. Representative microphotographs present intracellular AT8 immunoreactivity seen in the hippocampal CA3 region (h-j, 6 months), granular cell layer of the dentate gyrus (n, 9 months) and in the parietal and temporal cortex (b, c 1 month; e, f 3 months; l, m 9 months). Scale bar50 lm, except for h: scale bar 200 lm Staging of cognitive deficits 585 the individual susceptibility to streptozotocin as a characteristic feature of streptozotocin treatment in rats (Blokland and Jolles 1993; Prickaerts et al. 2000) . Decompensation manifested as a late progression of cognitive decline in this model may appear as a consequence of a self-propagating destructive process in the brain which, due to a selective toxicity of STZ to insulin-producing and IR-expressing cells (Giorgino et al. 1992; Kadowaki et al. 1984; Szkudelski 2001) , develops chronic insulin-resistant state with decreased glucose and energy metabolism (SalkovicPetrisic et al. 2009 ). This may further lead to a dysfunction of the particular neuronal cells with dysregulation of insulin receptor signaling pathways which results in pathological accumulation of hyperphosphorylated tau protein and Ab 1-42 and is manifested as memory decline. It seems most likely that this late, slowly developing, progressive memory decline is the one which better mimics the situation in sAD. Detection of 3-to 6-month period as a critical point after the STZ treatment has been seen in our previous research on this model also at the level of insulin-degrading TC temporal cortex, PC parietal cortex, HPC hippocampus, CA1 and CA3 regions of hippocampus, EM electron microscopy, STZ-icv streptozotocin-itracerebroventricularly-treated rats enzyme and glycogen synthase kinase-3b protein expression in the brain (Osmanovic- Barilar et al. 2014) . It is, thus, not surprising that the first morphological signs of amyloid pathology in our experiments appeared 3 months after the treatment with 3 mg/kg STZ-icv dose as intraneuronal Ab 1-42 accumulation (Fig. 7) . Our results show that it takes 6 months after the STZ-icv injection for the development of extracellular diffuse plaque-like Ab 1-42 aggregates in rat brain (Fig. 7) . Six months is also the approximate time needed for development of plaques in single-gene transgenic mice AD models that exhibit amyloid plaque pathology (PDAPP, APP23; McGowan et al. 2006) . Six months represent approximatively 25 % of a rat lifespan which, translated to humans, corresponds approximately to the development of clinical AD symptoms. To the best of our knowledge, this is the first morphological evidence of the generation of diffuse plaque-like accumulation of Ab 1-42 in the brain of non-transgenic rodents. Positive (non-aggregated) Ab 1-42 signal in other studies was detected before 3 months but after the treatment with STZ-icv doses 13 9 higher (40 mg/kg; Shingo et al. 2012 Shingo et al. , 2013 , which makes comparison with our data difficult.
Considering the fact that STZ induces nitroso-oxidative stress, the hypothesis that, by acting as a reactive oxygen scavenger, increased Ab response actually limits the oxidative damage (Smith et al. 2002) , fits well to the recent finding of increased Ab 1-42 ELISA immunoreactivity detected in homogenates of rat hippocampus 5 weeks after STZ-icv administration which has caused severe mitochondrial abnormalities in the brain (Correia et al. 2013) . Looking from this perspective, our results are complementary to the previously published data (Correia et al. 2013 , Shingo et al. 2012 . Namely, intracellular Ab 1-42 accumulation in the rat brain as early as few weeks after the STZ-icv administration might be generated as the acute compensatory effect whose detection could be related to its intensity (depending on a STZ-icv dose), the method and Ab 1-42 antibody used. Our experiments have shown that it takes much longer time after the STZ-icv administration for a development of a specific AD-like extracellular Ab 1- Fig. 6 Ultrastructural changes in the brain of STZ-icv-treated rats. The figure shows representative microphotographs of the neurons in (a-d) the granule cell layer of the dentate gyrus (DG) and (e-h) the pyramidal layers (CTX) in the streptozotocin (STZ, 3 mg/kg)-treated rats obtained 3, 6 and 9 months following the treatment. Representative microphotograph of control (CTRL) rats (6-month time point) is presented for comparison (i). The photomicrographs show the lysosomes and their dark granular content marked with white arrows (a-e), and pyknotic nucleus (f), enlargement of the Golgi apparatus with swollen terminal cisternae (g) and nuclear envelope invaginations (h) marked with black arrows. Scale bar is marked at each microphotograph Staging of cognitive deficits 587 42 accumulation. The time course of onset and progression of CAA followed up to 9 months after the STZ-icv administration supports this finding (Salkovic-Petrisic et al. 2011) . While the staging of AD by Braak and Braak (1997) is based on the neuropathological criteria only, more recent additional studies suggest cerebral vascular lesions (Jellinger 2013) and CAA (Thal et al. 2002a) as of importance in the pathology of AD. While small vascular lesions do not seem to influence rates of cognitive decline in AD (Lee et al. 2000) , clinicopathological studies by Grober and Fig. 7 Staging of cognitive deficits and underlying neuropathological and ultrastructural changes in the brain of a STZ-icv rat model. The figure presents the correlation of staging of cognitive deficits and structural/ultrastructural changes in a streptozotocin (STZ)-induced rat model of sporadic Alzheimer's disease (sAD). Data present findings obtained in animals treated intracerebroventricularly (icv) with 3 mg/kg STZ dose. Ultrastructural changes (pyknotic nuclei, lysosomal changes) of mild intensity appeared before (starting from 1 week after the STZ treatment) the structural changes and cognitive deficits in this experimental design (both starting from 1 month after the STZ treatment). The order of appearance in the 9-month post-STZ treatment period (from the earliest to the latest event) was: ultrastructural changes \early neurofibrillary changes (AT8) and acute cognitive decline \intracellular amyloid b 1-42 accumulation \extracellular plaque-like Ab 1-42 accumulation and chronic progressive cognitive decline. While ultrastructural and structural changes were both slowly progressing in the course of time, the cognitive deficits followed a triphasic pattern; (I) acute decline, (II) partial amelioration of cognitive decline, (III) chronic progressive cognitive decline. Three months after the STZ treatment seemed to be a critical point at which the pathological processes initiated by high STZ dose (3 mg/kg) could not be compensated any longer, resulting in a slow and progressive memory decline which correlated well with the first appearance of pathological Ab accumulation. Not only that pathological Ab accumulation appeared later than tau protein-related neurofibrillary changes and ultrastructural abnormalities, based on the arbitrary unit scale (0-5), but also it was of the lower intensity 9 months after the STZ treatment compared to neurofibrillary and ultrastructural changes (B3 vs B5). Considering the structural and ultrastructural changes observed in this 9-month follow-up, it seems most likely that the late, slowly developing, progressive memory decline in the STZ-icv rat model is the one which better mimics the situation in sAD coworkers (Grober et al. 1999) led to the conclusion that both memory and mental status performance correlate with a modified Braak staging procedure. Intracellular Ab may be a product of either an intracellular synthesis, internalization from an extracellular site or perhaps a combination of both (Nixon 2007) . Ineffective cellular degradation mechanisms may culminate in the progressive accumulation of aberrant protein aggregates and lysosomal burden in the AD brain (Cole et al. 1989; Haass et al. 2012) . Alterations of the neuronal endosomallysosomal system in AD have been found to precede degenerative changes, appearing at the earliest stage as lysosomal accumulation and at more advanced AD stages as lysosomal filling with abnormally large aggregates (Cataldo et al. 1994; Pimplikar et al. 2010) . In line with these data on human sAD lysosomal pathology, the ultrastructural changes presented here indicate increment in number, size, and density of lysosomes in the hippocampus and neocortex of STZ-icv-treated rats. Observed ultrastructural changes correlate with and may be speculate to reflect gradual accumulation of positive Ab 1-42 immunoreactivity in STZ-icv rats starting first intracellularly and then spreading extracellularly. This agrees with the recent evidence that Ab may actually begin to accumulate intracellularly in lysosomes (Agholme et al. 2012; Tam and Pasternak 2012) . In addition to increased lysosome numbers (Lopez et al. 2004) , research in transgenic AD mice models also indicated that intracellular accumulation of Ab 1-42 in the endosomal/lysosomal system appears either before or accompanying cognitive impairment, but well before the appearance of amyloid plaques (Knobloch et al. 2007; Wirths et al. 2001) .
Hyperphosphorylation of tau protein is one of the most important AD hallmarks. We have detected increased AT8 immunoreactivity (tau protein phosphorylated at Ser202/ Thr205 sites) in the parietal and temporal cortical regions as well as throughout the hippocampus of STZ-icv-treated (3 mg/kg) rats in the form of early neurofibrillary changes. As for Ab 1-42 , AT8 immunoreactivity increased in a timedependent manner, appearing first in neocortical regions 1 month after STZ-icv treatment and spreading to the hippocampal areas (Table 1) . To the best of our knowledge, this is the first in situ evidence of increased AT8 accumulation in STZ-icv rat model of sAD. Immunoblotting analysis has shown that 15 days after the STZ-icv treatment, the expression of phospho (Ser199/202) tau protein is increased in rat neocortex and basal ganglia; while no changes can be observed in the hippocampal region (Santos et al. 2012) . Clinical studies indicate that tau protein is modified at the site recognized by antibody AT8 much earlier than the appearance of aggregated (fibrillar) tau, suggesting that phosphorylation at the AT8 site represents an earlier change than tau aggregation (pretangle stage) (Braak et al. 1994; Delacourte et al. 1999) . These findings correlate well with our results of increased AT8 immunoreactivity but a lack of neurofibrillary tangles. Correlation of tau phosphorylation (recognized by AT8 antibody) in regions like CA3 with regression of synaptic components and memory deficits in AD patients (Spruston 2008) , supports our findings of cognitive deficits in parallel with AT8 immunoreactivity from 1 month post STZ-icv treatment. Indeed improved staging procedures based on neurofibrillary pathology (Alafuzoff et al. 2008; Braak et al. 2006 ) correlate well with the severity of cognitive impairment (Nelson et al. 2012 ). Accumulation of neuropathology (tangle counts in all human brain regions) appears to correlate with global cognitive decline as patients progress from MCI to AD (Sabbagh et al. 2010) . This is underlined by experimental studies in a transgenic mice AD model showing that Ab accelerates the spatiotemporal progression of tau pathology with augmentation of tau amyloidosis (Hurtado et al. 2010) .
In summary, the results presented here provide compelling evidence of the post-treatment time-and dose-dependent development of cognitive deficits, structural and ultrastructural changes, as well as diffuse Ab 1-42 plaquelike formations and early hyperphosphorylated tau proteinrelated neurofibrillary changes in the STZ-icv rat model 9 months after treatment. This study provides a comprehensive staging scheme of cognitive decline and neuropathogenesis in a non-transgenic rat model generated by induction of an insulin-resistant brain state, which eventually leads to the development of AD-like neuropathological changes. In line with the growing body of evidence suggesting that there may be different endophenotypes of sporadic AD (e.g., APOE4-negative individuals or pro-inflammatory phenotype/ Borroni et al. 2006) , STZ-icv model might be considered as sAD endophenotype associated with insulin-resistant brain state. While respecting all limitations that animal models designed to mimic a human disease carry with them, it cannot be ignored that alterations found in STZ-icv rat model at multiple levels (cognitive, neurochemical, structural and ultrastructural) correlate well with one another and converge to model the sAD condition. Validation of STZ-icv model as a representative sAD model by taking into account the presenting staging scheme may contribute to more successful data translation from non-clinical research based on this model to clinical AD trials.
